SEARCH:   Advanced

Blood, 1 July 2007, Vol. 110, No. 1, pp. 339-344. Prepublished online as a Blood First Edition Paper on March 22, 2007; DOI 10.1182/blood-2006-09-049189. This Article Abstract Full Text (PDF) All Versions of this Article: blood-2006-09-049189v1 110/1/339    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Liu, Y.-Y. Articles by Zhao, W.-L. Search for Related Content PubMed PubMed Citation Articles by Liu, Y.-Y. Articles by Zhao, W.-L. Related Collections Neoplasia Clinical Trials and Observations Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma Yan-Yan Liu1, Christophe Leboeuf2, Jing-Yi Shi1, Jun-Min Li1, Li Wang1, Yang Shen1, José-Francisco Garcia3, Zhi-Xiang Shen1, Zhu Chen1, Anne Janin2, Sai-Juan Chen1, and Wei-Li Zhao1 1 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2 Institut National de la Santé et de la Recherche Médicale (INSERM) U728, Université Paris VII, Institut d'Hématologie, Hôpital Saint Louis, Paris, France; 3 The Monoclonal Antibodies Unit, Biotechnology Program, Spanish National Cancer Center (CNIO), Madrid, Spain    Abstract Top Abstract Introduction Patients, materials, and methods Results Discussion Authorship References   The positive regulatory domain I (PRDM1) is a master regulator in the differentiation of mature B lymphocytes to plasma cells. It has 2 isoforms, PRDM1 and PRDM1ß, and is regulated by the transcriptional regulator nuclear factor kappa (NF)–B. PRDM1 protein expression was recently demonstrated in a subset of diffuse large B-cell lymphoma (DLBCL) with aggressive behavior, a type of lymphoma for which rituximab associated with chemotherapy (R-CHOP) is now widely indicated. Using laser microdissection combined with reverse transcription–polymerase chain reaction (RT-PCR) amplification, PRDM1 gene expression was assessed in 82 DLBCL patients. The results showed that both PRDM1 and PRDM1ß transcripts were expressed in microdissected lymphoma cells only in the non–germinal center B-cell–like (non-GCB) subtype of DLBCL. PRDM1ß gene expression was correlated with short survival time in the non-GCB patients treated with CHOP but not with R-CHOP. In vitro, B-lymphoma cells resistant to chemotherapy expressed PRDM1ß. Rituximab suppressed PRDM1ß expression, which was concomitant with NF-B inactivation. The value of PRDM1ß expression as a prognostic marker in non-GCB DLBCL might thus be considered. This study confirms the efficiency of rituximab on DLBCL and allows a better understanding of one of its biologic actions.    Introduction Top Abstract Introduction Patients, materials, and methods Results Discussion Authorship References   Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell lymphoma and represents a heterogeneous group of tumors on morphologic, phenotypic, molecular, and clinical grounds.1 Using gene-expression profiling, DLBCL has been classified as 3 distinct subtypes, which reflect different stages of B-cell differentiation. Germinal center B-cell–like (GCB) DLBCL presumably derives from GC centroblasts and is associated with a good outcome. Activated B-cell–like (ABC) DLBCL has the expression pattern of GC cells undergoing plasmacytic differentiation or of mitogen-activated peripheral B cells and is associated with a poor outcome.2,3 The type 3 group behaves in a manner similar to the ABC group.4 The protein expression patterns of CD10, BCL-6, and IRF4 (also known as MUM1) are alternative means of identifying the GCB and non-GCB groups, the latter corresponding to the microarray-defined ABC and type 3 phenotype.5 Rituximab (Rituxan; IDEC-C2B8), a recombinant chimeric monoclonal antibody against the pan–B-cell marker CD20, has shown promising results in the clinical treatment of patients with DLBCL.6 Addition of rituximab to chemotherapy can modify the adverse prognostic significance of the ABC phenotype.7 To further determine the role of B-cell differentiation on DLBCL development, related genes should be studied. The positive regulatory domain I (PRDM1), belonging to the PRDM gene family of transcriptional repressors, plays a central role in the terminal differentiation of B cells to plasma cells.8,9 PRDM1 is positively regulated by NF-B. In B cells, PRDM1 gene expression can be induced in M12 and CH12 lymphoma lines. This induction is dependent on NF-B because Helenalin, an inhibitor specific for NF-B, inhibits PRDM1 expression.10 PRDM1 was found to be inactivated in the non-GCB subtype of DLBCL and is considered a potential tumor suppressor gene in these lymphomas.11–13 However, PRDM1 protein expression has been recently reported in a sizable fraction of DLBCL, which displayed more aggressive behavior, with a shorter failure-free survival.14 PRDM1 exists as 2 isoforms, PRDM1 and PRDM1ß. Generated from the same gene by alternative transcription, PRDM1ß differs from PRDM1 by lacking the amino-terminal 101 amino acids and having a disrupted PR domain. It is functionally impaired, with loss of repressive function on multiple target genes.15 The prognostic significance of PRDM1 isoform expression has not yet been reported in DLBCL. Using laser microdissection combined with reverse transcription–polymerase chain reaction (RT-PCR) amplification, we assessed the respective expression of the 2 PRDM1 isoforms in 82 DLBCL patients and their prognostic value. We further studied the PRDM1 expression in B-lymphoma cell lines and their variations when treated by doxorubicin and/or rituximab.    Patients, materials, and methods Top Abstract Introduction Patients, materials, and methods Results Discussion Authorship References   Patients From January 2001 to June 2006, 82 patients with de novo DLBCL, 49 men and 33 women aged 18 to 84 years (median, 51 years), treated in the Shanghai Institute of Hematology–based patient network with available frozen tumor specimen at diagnosis, were included in this retrospective study. Histologic diagnoses were established according to the World Health Organization classification. The patients were treated with the standard dose of chemotherapy alone (CHOP regimens) or combined with rituximab (R-CHOP regimens). The clinical features of these patients are listed in Table 1. No significant difference in sex, age, Ann Arbor stage, or international prognostic index (IPI) was found between the 2 groups. Informed consent was obtained from all patients, in accordance with regulation of the Shanghai Jiao Tong University School of Medicine Institutional Review Boards. View this table: [in this window] [in a new window]   Table 1. Clinical characteristics of the DLBCL patients   Tissue samples Tumor samples at time of diagnosis were immediately cut into 2 parts: one part was fixed in formaldehyde and further processed for paraffin embedding and the other was snap-frozen and stored at –80°C. Cell lines Cell lines U266, SU-DHL-4, Daudi, and Namalwa were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (Gibco/BRL, Grand Island, NY) in 5% CO2, 95% air-humidified atmosphere at 37°C. Namalwa cells, with features of non-GCB and resistant to doxorubicin,16 were treated with doxorubicin, rituximab, or pyrrolidine dithiocarbamate (PDTC; Sigma, St Louis, MO) that specifically inhibits the NF-B activation.17 Cell viability was assessed by triplicate count of trypan blue test. Immunohistochemistry Immunohistochemical analyses were performed on 5-µm–thick paraffin sections with an indirect immunoperoxidase method, using antibodies against CD10 (Novocastra, Newcastle, United Kingdom; 1:80), Bcl-6 (Dako, Glostrup, Denmark; 1:10), IRF4 (Dako; 1:40), and PRDM1 (one from Novus Biologicals, Littleton, CO; 1:50; and another from the Monoclonal Antibodies Unit, Biotechnology Program, Spanish National Cancer Center, Madrid, Spain; 1:2). The slides were viewed on a Leica CTR MIC microscope (Leica Microsystem, Wetzlar, Germany), photographed by a 3CCD camera (HV-C20AMP, Hitachi Kokusai Electric Inc., Tokyo, Japan) using image-acquisition software Matrox Intellicam Version 2.06 (Matrox Electronic Systems Ltd., Dorval, Quebec, Canada). Laser microdissection Seven µm–thick frozen sections of DLBCL were incubated in RNAse-free conditions with anti-CD20 (Dako; 1:50) or IRF4 (Dako; 1:10) antibody for 5 minutes and then in fluorescein-conjugated goat anti–mouse IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, PA; 1:50) for 5 minutes. Laser microdissection of fluorescent cells was immediately performed (Leica Microsystem) for RNA extraction. Semiquantitative RT-PCR Total RNA was extracted from whole frozen tissue sections, laser-microdissected lymphoma cells, or cultured cells using Trizol reagent (Invitrogen, Carlsbad, CA). First-strand cDNA was synthesized by Superscript II reverse transcriptase (Invitrogen) according to the manufacturer's instructions. Semiquantitative PCR was performed using primers listed in Table 2. The housekeeping GAPDH gene was used as control. View this table: [in this window] [in a new window]   Table 2. Primers used in the semi-quantitative PCR studies   Sequence analysis of PRDM1 Genomic DNA was extracted from frozen tissue sections using standard proteinase K digestion and phenol/chloroform procedures. The resultant PCR products were purified on Qiagen columns (Qiagen, Valencia, CA) and sequenced by PRDM1 primers on ABI PRISM 3700 DNA Analyzer using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA). Western blot Frozen tissue sections or cultured cells were lysed in 200 µL lysis buffer (0.5 M Tris-HCl, pH 6.8; 2 mM EDTA; 10% glycerol; 2% SDS; and 5% ß-mercaptoethanol). Protein extracts (20 µg) were loaded onto 10% polyacrylamide gel containing sodium dodecyl sulfate, subjected to electrophoresis, and transferred to nitrocellulose membranes. Membranes were blocked with 5% nonfat dried milk in Tris-buffered saline (TBS) /0.05% Tween 20 and incubated for 2 hours at room temperature with appropriate primary antibody, followed by treatment with horseradish peroxidase–linked secondary antibody. The immunocomplexes were visualized using chemiluminescence phototope-horseradish peroxidase kit. Detection of ß-actin was performed to ensure equivalent protein loading. Enzyme-linked immunosorbent assay (ELISA) analysis for NF-B activity Most actively involved in NF-B signaling, NF-B (P65) phosphorylation at serine 276 allows for increased interaction with the transcriptional coactivator p300/CBP to enhance its transcriptional activity.18 Total NF-B, phosphorylated NF-B, activated form of NF-B (nuclear localization sequence of P65), and GAPDH were detected by KC NF-B Pathway ELISA Kit (KangChen Biotech, Shanghai, China) according to the manufacturer's instructions. Statistical analysis Patient characteristics were compared using 2 analysis and the Fisher exact test. Overall survival (OS) was measured from the time of diagnosis to either death or the end date of August 31, 2006. Event-free survival (EFS) was calculated from the time of diagnosis to the date of progression, death, or the end date. When the end date was not reached, the data were censored at the date of the last follow-up evaluation. Survival functions were estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariate survival analysis was performed using a Cox regression model. P less than .05 was considered to be significant. All statistical analyses were performed on SAS 8.2 software (SAS Institute, Cary, NC).    Results Top Abstract Introduction Patients, materials, and methods Results Discussion Authorship References   PRDM1 was predominantly expressed in the non-GCB subtype of DLBCL As defined by immunostainings on paraffin sections using antibodies against CD10, BCL-6, and IRF4,5 33 (40.2%) of the 82 patients had a GCB phenotype and 49 (59.8%) had a non-GCB phenotype. PRDM1 protein expression was not significantly different in GCB (13/33, 39.4%) and non-GCB (24/49, 49.0%) DLBCL. However, PRDM1 and PRDM1ß transcripts were more frequently observed in the non-GCB subtype (73.5% and 38.8%, respectively) than in the GCB subtype (39.4% and 6.1%, respectively; P = .002 and P < .001; Table 3). While all 13 GCB cases expressed the PRDM1 transcript and protein at the same time, 12 of the 36 non-GCB patients positive for PRDM1 transcript had no PRDM1 protein expression. In turn, PRDM1 protein was detected in the 19 patients expressing PRDM1ß transcripts. View this table: [in this window] [in a new window]   Table 3. PRDM1 transcripts and protein expressions in DLBCL patients   Systematic sequencing of PRDM1 in these 82 patients showed no mutation, including the previously described mutational hot spot (exon 2/intron 2 junction).11 PRDM1 transcripts and protein were expressed in lymphoma cells of non-GCB DLBCL and related to IRF4 expression PRDM1 protein was expressed in a larger number of cells in non-GCB DLBCL compared with GCB cases (Figure 1A-B). To confirm the PRDM1 gene expression in lymphoma cells, we isolated CD20+ cells by laser microdissection. Both PRDM1 transcripts were detected in microdissected non-GCB lymphoma cells (Figure 1A). Although expressed in whole lymphoma tissue sections, neither PRDM1 nor PRDM1ß messenger RNA (mRNA) was found in the microdissected GCB lymphoma cells at the same level as mRNA for the GAPDH gene (Figure 1B). View larger version (62K): [in this window] [in a new window]   Figure 1. PRDM1 was expressed in lymphoma cells of non-GCB DLBCL and related to IRF4 expression. With different protein expression patterns revealed by immunohistochemisty (A-B), PRDM1 transcripts were expressed in microdissected lymphoma cells of DLBCL non-GCB subtype (A) but not of GCB subtype (B) (40x/0.75 NA non-oil objective). PRDM1 expression was related to IRF4 expression (C). IRF4-positive lymphoma cells coexpressed IRF4, PRDM1, and PRDM1ß (D) (10x/0.75 NA non-oil objective; small figure: 150x/0.75 NA non-oil objective).   Interestingly, PRDM1 was significantly related to IRF4 expression (Figure 1C): it was found in 17 (65.4%) of 26 IRF4-positive non-GCB DLBCL patients but in only 7 (30.4%) of 23 IRF4-negative cases (P = .015). At the transcriptional level, laser-microdissected IRF4-positive cells expressed mRNA of IRF4, PRDM1, and PRDM1ß (Figure 1D). PRDM1ß expression was independently related to short survival time in non-GCB DLBCL patients treated by CHOP but not in those treated by R-CHOP Of the 49 non-GCB DLBCL patients, 24 received CHOP and 25 received R-CHOP. In the CHOP group, the 3-year EFS and OS rates (± SE percentage) for patients with PRDM1ß gene expression were 14.3% (± 3.2%) and 35.7% (± 19.7%), respectively, significantly shorter than those without PRDM1ß gene expression (65.9% [± 14.3%] and 85.7% [± 13.2%], P = .026 and P = .017, respectively). Using multivariate analysis, PRDM1ß expression was an independent adverse prognostic factor for EFS and OS (P = .029 and P = .007, respectively). The Cox model selected 4 criteria for survival: age, sex, Ann Arbor stage, and IPI. In the R-CHOP group, however, the decreased survival was no longer observed in patients with PRDM1ß expression, both for EFS (P = .213) and OS (P = .358). No correlation was found between PRDM1 gene expression and survival or between PRDM1 protein expression and survival. PRDM1ß transcript and protein were expressed in lymphoma cells and down-regulated after treatment with rituximab and doxorubicin By RT-PCR, PRDM1 transcript was detected in a series of B-lymphoma cell lines, human tonsil, as well as non-GCB DLBCL samples, whereas no PRDM1ß transcript was found in human tonsil (Figure 2A). PRDM1 and PRDM1ß protein profile revealed by Western blot followed mRNA variations (Figure 2B). PRDM1ß protein was identified as a fragment at about 70 kDa in B-lymphoma cell lines and the patient samples, different from an 80-kDa PRDM1ß protein found in myeloma cell line U266. No PRDM1ß protein was observed in human tonsil. View larger version (42K): [in this window] [in a new window]   Figure 2. Rituximab combined with doxorubicin down-regulated PRDM1ß expression. B-lymphoma cell lines and primary DLBCL cells expressed PRDM1 and PRDM1ß both at transcriptional (A) and protein levels (B). Combined treatment of doxorubicin and rituximab reduced PRDM1ß expression (C-D).   Namalwa cells were treated with different concentrations of doxorubicin (1, 5, 10, 20, and 50 ng/mL), alone or combined with rituximab (100 µg/mL), for 48 hours. Doxorubicin alone did not inhibit cell proliferation at concentrations up to 50 ng/mL, but doxorubicin with rituximab had a significant antiproliferative effect at 20 ng/mL (15.8% ± 0.7% vs 2.1% ± 0.2%, respectively, P > .001) and 50 ng/mL (29.3% ± 1.2% vs 5.2% ± 0.6%, respectively, P < .001). After 12 and 24 hours of incubation with doxorubicin (50 ng/mL) and rituximab (100 µg/mL), a decreased expression of PRDM1ß gene, but not of PRDM1 gene, was found compared with each agent alone (Figure 2C). The PRDM1ß protein level followed a similar reduction, observed later at 24 and 48 hours after treatment (Figure 2D). Rituximab inhibited NF-B activity in B-lymphoma cells and this could be mimicked by the NF-B inhibitor PDTC To determine if NF-B activity was altered, sequential ELISA assays were performed at 6 and 12 hours in Namalwa cells. The level of phosphorylated NF-B was significantly lower in the cells cotreated with doxorubicin (50 ng/mL) and rituximab (100 µg/mL) compared with each drug alone (Figure 3A). This was concomitant with a reduction of activated NF-B, without change of total NF-B. View larger version (33K): [in this window] [in a new window]   Figure 3. Rituximab combined with doxorubicin decreased NF-B activity. Rituximab combined with doxorubicin significantly decreased the phosphorylated and the activated forms of NF-B (P65) in Namawa cells, without variation of total NF-B (A). Addition of NF-B inhibitor PDTC increased the antiproliferative effect of doxorubicin on Namawa cells (B) and induced PRDM1ß down-regulation (C).   When treated with doxorubicin (50 ng/mL) and PDTC (20 µM), an inhibitor of NF-B activation, Namalwa cells showed a progressive growth inhibition (Figure 3B) with parallel decrease of the PRDM1ß protein level (Figure 3C).    Discussion Top Abstract Introduction Patients, materials, and methods Results Discussion Authorship References   In the present study, we showed that aberrant gene and protein expression of PRDM1 occurred in DLBCL and was particularly relevant to the non-GCB phenotype. Since PRDM1 transcript could be detected on lymphoma cells, as well as associated nonmalignant cells like plasma or reactive T cells,14 laser microdissection allowed us to confirm that lymphoma cells in non-GCB DLBCL expressed both isoforms of PRDM1 gene. Repeated microdissection and semiquantitative RT-PCR, however, did not detect any expression of PRDM1 gene in GCB lymphoma cells. This is in accordance with the new DLBCL classification, which suggests that the GCB subtype of lymphoma derives from GC B centroblasts that do not normally express PRDM1.19 At the protein level, no significant difference in PRDM1 expression was found between the non-GCB and GCB groups. The discrepancy from PRDM1 transcript to protein expression had also been reported in another non-GCB DLBCL series.12 Although no gene mutation was detected, other genetic and epigenetic inactivation as well as defects in protein translation or stability might contribute to the lack of PRDM1 protein expression in non-GCB DLBCL.12 No discrepancy in transcript and protein expressions was found for the isoform PRDM1ß notifying it as a specific lesion in non-GCB DLBCL. PRDM1ß is highly analogous to the PRDM2 (RIZ) and PRDM3 (MDS1-EVI1), both expressing a truncated protein missing the PR domain. These truncated proteins are expressed in different types of malignant cells and critical for oncogenesis.20–23 Our study demonstrated that the PRDM1ß was present in both B-lymphoma cell lines and primary DLBCL cells. Statistical analyses showed that PRDM1ß expression was an independent adverse prognostic factor for EFS and OS in non-GCB DLBCL. Therefore, PRDM1ß may favor lymphoma progression in DLBCL. PRDM1ß coexpressed with IRF4 in 17 of 49 of our non-GCB cases. IRF4 is a lymphoid-specific transcriptional regulator and denotes the final step of GCB cell differentiation toward plasma cells.24,25 Originally identified as the product of a proto-oncogene in multiple myeloma,26 IRF4 is often abnormally expressed in B-cell lymphomas.27 This IFR4-PRDM1ß coexpression suggested that PRDM1ß happens with IRF4 during later B-cell maturation. It might also interact with IRF4 and contribute to lymphomagenesis.28 An unexpected observation was that PRDM1ß expression was significantly correlated with short survival time in patients treated by CHOP but not by R-CHOP. Since it was a retrospective study, patient selection for treatment could possibly influence the results. This must be further verified in a randomized trial. In vitro, rituximab enhances lymphoma cell sensitivity to chemotherapeutic drugs through inhibition of the NF-B pathway.29 Experimental studies also showed that NF-B is able to regulate PRDM1.10,30 In our study, rituximab combined with doxorubicin could inhibit NF-B activity in B lymphoma cells, resulting in reduced PRDM1ß expression. To test this hypothesis, we associated PDTC, an inhibitor or NF-B, with doxorubicin in lymphoma cell cultures. The induced growth inhibition, similar to rituximab treatment, confirmed that NF-B activity was responsible for PRDM1ß down-regulation by rituximab. Rituximab could overcome the adverse prognostic effect of PRDM1ß in the non-GCB DLBCL patients. Interestingly, another clinical study also reported the effect of rituximab on chemo-resistant DLCBL with the expression of BCL-2,31 another biomarker regulated by NF-B.32 Therefore, the action of rituximab in B-lymphoma cells might be linked to interactions of NF-B with multiple gene products. This further raises the question of the prospective identification of B-cell lymphoma patients for rituximab therapy through a test of NF-B activity. In conclusion, abnormal expression of PRDM1, particularly of its isoform PRDM1ß, was restricted to lymphoma cells of the non-GCB subtype in DLBCL. Addition of rituximab could down-regulate PRDM1ß expression, reversing the negative effect of PRDM1ß on chemotherapy-treated patients.    Authorship Top Abstract Introduction Patients, materials, and methods Results Discussion Authorship References   Contribution: W.-L.Z., A.J., S.-J.C., and Z.C. designed research and wrote the paper; Y.-Y.L., C.L., J.-Y.S., and L.W. performed research; J.-F.G. contributed vital new reagents; J.-M.L. and Z.-X.S. collected data; and Y.S. analyzed data. Y.Y.L., C.L., and J.-Y.S. contributed equally to this work. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Wei-Li Zhao and Sai-Juan Chen, State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai 200025, China; e-mail: weili_zhao_sih{at}yahoo.com and sjchen{at}stn.sh.cn.    Acknowledgments   This work was supported in part by the Chinese National Key Program for Basic Research (973: 2004CB518600), the Chinese National High Tech Program (863: 2006AA02A301 and 863:2006AA02A405), the Key Discipline Program of Shanghai Municipal Education Commission (Y0201), the Shanghai Commission of Science and Technology (44107025 and 05DZ19317), the Shanghai Rising Star Program (05QMX1429), the Scientific Research Foundation for the Returned Overseas Chinese Scholars, the Program de Recherches Avancées (PRA B 03–02 and PRA B 05–02), and the Samuel Waxman Cancer Research Foundation Laboratory.    Footnotes   Submitted September 28, 2006; accepted March 16, 2007. Prepublished online as Blood First Edition Paper, March 22, 2007 DOI: 10.1182/blood-2006-09-049189 The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.    References Top Abstract Introduction Patients, materials, and methods Results Discussion Authorship References   Abramson JS and Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106:1164–1174.[Abstract/Free Full Text] Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503–511.[CrossRef][Medline] [Order article via Infotrieve] Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002; 2:920–932.[CrossRef][Medline] [Order article via Infotrieve] Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937–1947.[Abstract/Free Full Text] Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275–282.[Abstract/Free Full Text] Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635–2642.[Abstract/Free Full Text] Wilson WH, Dunleavy K, Pittaluga S. Dose-adjusted EPOCH-rituximab is highly effective in the GCB and ABC subtypes of untreated diffuse large B-cell lymphoma [abstract]. Blood 2004; 104:49a Abstract 159. Shapiro-Shelef M, Lin KI, Savitsky D, Liao J, Calame K. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med 2005; 202:1471–1476.[Abstract/Free Full Text] Shapiro-Shelef M and Calame K. Regulation of plasma-cell development. Nat Rev Immunol 2005; 5:230–242.[CrossRef][Medline] [Order article via Infotrieve] Johnson K, Shapiro-Shelef M, Tunyaplin C, Calame K. Regulatory events in early and late B-cell differentiation. Mol Immunol 2005; 42:749–761.[CrossRef][Medline] [Order article via Infotrieve] Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006; 107:4090–4100.[Abstract/Free Full Text] Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006; 203:311–317.[Abstract/Free Full Text] Cattoretti G, Angelin-Duclos C, Shaknovich R, Zhou H, Wang D, Alobeid B. PRDM1/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage. J Pathol 2005; 206:76–86.[CrossRef][Medline] [Order article via Infotrieve] Garcia JF, Roncador G, Sanz AI, et al. PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica 2006; 91:467–474.[Abstract/Free Full Text] Gyory I, Fejer G, Ghosh N, Seto E, Wright KL. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J Immunol 2003; 170:3125–3133.[Abstract/Free Full Text] Liu C, Lambert JM, Teicher BA, Blattler WA, O'Connor R. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. Blood 1996; 87:3892–3898.[Abstract/Free Full Text] Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 1992; 175:1181–1194.[Abstract/Free Full Text] Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998; 1:661–671.[CrossRef][Medline] [Order article via Infotrieve] Angelin-Duclos C, Cattoretti G, Lin KI, Calame K. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol 2000; 165:5462–5471.[Abstract/Free Full Text] Sasaki O, Meguro K, Tohmiya Y, Funato T, Shibahara S, Sasaki T. Altered expression of retinoblastoma protein-interacting zinc finger gene, RIZ, in human leukaemia. Br J Haematol 2002; 119:940–948.[CrossRef][Medline] [Order article via Infotrieve] Cuenco GM, Nucifora G, Ren R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc Natl Acad Sci U S A 2000; 97:1760–1765.[Abstract/Free Full Text] Chadwick RB, Jiang GL, Bennington GA, et al. Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc Natl Acad Sci U S A 2000; 97:2662–2667.[Abstract/Free Full Text] He L, Yu JX, Liu L, et al. RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res 1998; 58:4238–4244.[Abstract/Free Full Text] Klein U, Casola S, Cattoretti G, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 2006; 7:773–782.[CrossRef][Medline] [Order article via Infotrieve] Gaidano G and Carbone A. MUM1: a step ahead toward the understanding of lymphoma histogenesis. Leukemia 2000; 14:563–566.[CrossRef][Medline] [Order article via Infotrieve] Iida S, Rao PH, Butler M, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 1997; 17:226–230.[CrossRef][Medline] [Order article via Infotrieve] Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95:2084–2092.[Abstract/Free Full Text] Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 2006; 25:225–236.[CrossRef][Medline] [Order article via Infotrieve] Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005; 65:264–276.[Abstract/Free Full Text] Doody GM, Stephenson S, Tooze RM. BLIMP-1 is a target of cellular stress and downstream of the unfolded protein response. Eur J Immunol 2006; 36:1572–1582.[CrossRef][Medline] [Order article via Infotrieve] Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2–associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101:4279–4284.[Abstract/Free Full Text] Catz SD and Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001; 20:7342–7351.[CrossRef][Medline] [Order article via Infotrieve] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: Response: Multiple role of PRDM1β involvement in diffuse large B-cell lymphoma Wei-Li Zhao, Anne Janin, and Sai-Juan Chen Blood 2008 111: 2489-2490. [Full Text] [PDF] Is early, deep free light chain response really an adverse prognostic factor? Angela Dispenzieri Blood 2008 111: 2490-2491. [Full Text] [PDF] This article has been cited by other articles: B. D. Cheson and J. P. Leonard Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma N. Engl. J. Med., August 7, 2008; 359(6): 613 - 626. [Full Text] [PDF] W. H. Wilson, K. Dunleavy, S. Pittaluga, U. Hegde, N. Grant, S. M. Steinberg, M. Raffeld, M. Gutierrez, B. A. Chabner, L. Staudt, et al. Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers J. Clin. Oncol., June 1, 2008; 26(16): 2717 - 2724. [Abstract] [Full Text] [PDF] W.-L. Zhao, Y.-Y. Liu, Q.-L. Zhang, L. Wang, C. Leboeuf, Y.-W. Zhang, J. Ma, J.-F. Garcia, Y.-P. Song, J.-M. Li, et al. PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor Blood, April 1, 2008; 111(7): 3867 - 3871. [Abstract] [Full Text] [PDF] W. Tam, M. Gomez, and K. Nie Significance of PRDM1{beta} expression as a prognostic marker in diffuse large B-cell lymphomas Blood, February 15, 2008; 111(4): 2488 - 2489. [Full Text] [PDF] W.-L. Zhao, A. Janin, and S.-J. Chen Response: Multiple role of PRDM1{beta} involvement in diffuse large B-cell lymphoma Blood, February 15, 2008; 111(4): 2489 - 2490. [Full Text] [PDF] F. Mora-Lopez, E. Reales, J. A. Brieva, and A. Campos-Caro Human BSAP and BLIMP1 conform an autoregulatory feedback loop Blood, November 1, 2007; 110(9): 3150 - 3157. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: blood-2006-09-049189v1 110/1/339    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Liu, Y.-Y. Articles by Zhao, W.-L. Search for Related Content PubMed PubMed Citation Articles by Liu, Y.-Y. Articles by Zhao, W.-L. Related Collections Neoplasia Clinical Trials and Observations Related Articles in Blood Online Social Bookmarking                   What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020